Skip to main content
Caplight Logo









Kupando

Kupando

Private
SchönefeldConsumer & Commercehttps://www.kupando.com/

Last Round

Series A

Extension

Mar 18, 2026

Total Funding Raised

$24.09M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Kupando is a biopharmaceutical company developing small-molecule immunotherapies that stimulate the innate immune system to address unmet needs in oncology and infectious diseases.

Sector

Consumer & Commerce

Verticals

E-commerce, Supply Chain, Workflow Automation

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug developmentbiotechclinical-stage biotechTLR agonistcancer therapyinfectious diseasedrug pipelinepreclinical researchpharmadrug discoverybiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kupando Comparables

Compare Kupando with similar companies based on industry and business-model similarity.

Kupando comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Kupando Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionMar 18, 2026
Series ASep 26, 2022

Kupando Investors

Notable investors and investment history

Kupando investors
InvestorRounds
Investitionsbank des Landes BrandenburgSeries A Extension
LifeCare PartnersSeries A Extension, Series A
Remiges VenturesSeries A Extension, Series A
Brandenburg KapitalSeries A Extension, Series A
Ventura BioMed InvestorsSeries A Extension, Series A
CARMA FUNDSeries A Extension
High-Tech GründerfondsSeries A Extension, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 18, 2026

    $11.5M raised in Series A Extension round.

  • Sep 26, 2022

    $13M round led by LifeCare Partners and Remiges Ventures.

Kupando Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kupando Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kupando's valuation, stock price, and market status.

Firmographic Details

HeadquartersSchönefeld
Employee Range12
Year Founded2018
Last FundingMar 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?